Anandamide: the endocannabinoid named after ananda

A molecule that fits a receptor

Mechanism first. Anandamide is a compound the body produces itself, and the property that defines it is binding to the cannabinoid receptor [1]. That property is the whole reason it gets grouped with the cannabinoids of the hemp plant, and it is where the class name comes from: endogenous cannabinoid, shortened to endocannabinoid. Endogenous just means made inside the body rather than taken in from outside. Chemically, anandamide belongs to the fatty acid ethanolamides. So the picture is straightforward at its core. A signalling molecule built in the body, reaching a receptor that pharmacologists already knew about, and giving that receptor an internal partner it had been missing. Anandamide sits at the centre of the endocannabinoid system [1].

Made in the body, cleared by an enzyme

A signal that switches on has to switch off. For anandamide, the off switch is enzymatic. An enzyme breaks the molecule apart, and the signal ends there [1]. That single detail shaped much of the research that came after. A large share of the later literature does not add anandamide to a system at all. It slows the removal instead, then records what happens further along the chain. The observation is indirect by design: leave the body's own molecule in place for longer, and watch the consequences, rather than flooding a preparation with an outside supply. Worth remembering when you read something about raising anandamide levels. In experimental systems, that phrasing usually describes interference with clearance, and what gets measured is a downstream effect in that system. The enzyme is not a footnote to the mechanism. It is part of it.

One report, one brain constituent, 1992

Before 1992, the cannabinoid receptor was a receptor without a known internal partner. That was the open question. A binding site existed in mammalian tissue, and nobody had shown what the body itself sent to it. Devane and colleagues closed that gap in 1992. Their report describes a constituent isolated from brain tissue, gives its structure, and demonstrates that it binds the cannabinoid receptor [1]. Three things in one paper: isolation, structure, binding. Anandamide came first in the isolation order, and the name arrived with it. Ananda, from Sanskrit, joined to amide, the chemical ending. It is the detail about anandamide that people repeat most often, and it is worth being clear about what kind of detail it is. A naming choice made by the researchers who isolated the compound from brain tissue [1]. Not a measured effect.

The question changed subject

The consequence of 1992 was a change of subject. Before the isolation, cannabis pharmacology was a question about a plant: which compounds does it contain, and what do they bind. After the isolation, the subject became a signalling system resident in mammals, with its own molecules, its own receptors and its own clearance enzymes. Plant cannabinoids kept their place in the story, but as compounds that partly fit a system the body already runs. That is a different kind of question, and it is the reason the endocannabinoid system has its own literature today rather than a chapter inside cannabis chemistry.

Eight points on the record

1. Anandamide was isolated from brain tissue in 1992, and the report that describes the isolation also determines the structure [1].
2. The same 1992 report demonstrates binding to the cannabinoid receptor, which is the property that defines the compound and places it in the endocannabinoid class [1].
3. The name combines the Sanskrit ananda with the chemical suffix amide, a choice made by the researchers who isolated the compound [1].
4. Anandamide is a fatty acid ethanolamide, a chemical family distinct from the one 2-AG belongs to.
5. 2-AG is a monoacylglycerol, and it is commonly described as the more abundant of the two in brain tissue.
6. Clearance of anandamide is enzymatic, which means the signal ends when an enzyme breaks the molecule down [1].
7. The enzyme that clears 2-AG is monoacylglycerol lipase, so the two endocannabinoids are removed by different enzymes.
8. Fenwick and colleagues reported in 2017 that anandamide directly activates TRPV1, a sensory ion channel, and that the calcium and current readings from that activation diverge rather than track one another [2].

Past the cannabinoid receptor: a sensory channel

The cannabinoid receptor is where the story starts, not where it ends. In 2017, Fenwick and colleagues reported direct activation of TRPV1 by anandamide [2]. TRPV1 is a sensory ion channel, a pore in the cell membrane that opens and lets ions through. So this is a second kind of target, working by a different route from a classical receptor. What the paper describes is a mechanistic finding about a molecule and a channel. Nothing more than that, and the scope matters. This is one group, one publication, from 2017. It is not a health outcome, not a dose, and not a statement about people [2]. Additional targets for anandamide, including this channel report, sit in the literature as individual findings rather than settled consensus [2].

Two readouts, one interaction

The interesting technical part is the divergence. Calcium responses and current responses did not follow each other [2]. Same interaction, two ways of measuring it, two different-looking answers. That is a measurement observation before it is anything else, and it is a good reminder of how mechanistic work actually reads: the picture you get depends on the readout you chose. Anyone summarising the study in a single sentence about what anandamide does to sensory nerves has gone past what the paper measured. The honest version stays flat. Direct activation of the channel was shown, the two readouts came apart, and the authors are the ones to credit for both parts.

Anandamide next to 2-AG

Ask what separates the two endocannabinoids that dominate the literature, and the first answer is chemistry. Anandamide is a fatty acid ethanolamide. 2-AG is a monoacylglycerol. Different families, different molecular build, both binding the same cannabinoid receptors. That is why they get discussed as a pair. Discovery order is the second answer: anandamide came first, isolated from brain tissue in 1992 [1]. The third is abundance, where 2-AG is commonly described as the more plentiful of the two in brain tissue. Three plain differences, none of them a ranking of importance.

Two molecules, two clearance enzymes

Removal is where the pair separates most clearly. Each compound has its own enzyme. For 2-AG, that enzyme is monoacylglycerol lipase. For anandamide, clearance is enzymatic as well, described in the same body of work that established the compound itself [1]. This matters for reading experiments. When a study slows the breakdown of one endocannabinoid, it is acting on one enzyme, and the other molecule is not automatically along for the ride. It also explains why the two appear in separate experimental setups so often, with separate tools, even when the receptor at the end of the chain is shared. Same class, same receptor, different chemistry, different exit route. That is the whole comparison, and it holds without any need to declare one of them the main endocannabinoid.

Where this page stops

This page follows the same rule a lab report follows: describe what was shown, name the mechanism that ends the signal, and stop at the limit of the evidence. Working with cannabinoids since 2014 has taught us that the limit is the useful part. Attribution comes before enthusiasm, so the two cited studies are named by year and author, and their scope is stated rather than stretched.

• Documented in 1992: isolation from brain tissue, the structure of the compound, and binding to the cannabinoid receptor [1].
• Documented as mechanism: clearance is enzymatic, which is what terminates the signal [1].
• Documented in 2017: direct activation of the TRPV1 sensory ion channel by anandamide, with calcium and current responses that do not track each other [2].
• A naming choice, not a measurement: ananda plus amide, chosen by the researchers who isolated the compound [1].
• Not covered by either cited study: any health outcome, any dose, any statement about what happens in people [2].
• Not settled consensus: the broader set of additional targets, including the 2017 channel report, which stands as an individual finding [2].
• Open by nature: how a divergence between two readouts of the same interaction should be interpreted, since the appearance depends on the measurement [2].
• Kept separate here: cannabis pharmacology as a question about a plant, and the endocannabinoid system as a question about a signalling system the body runs itself.